CA3177056A1 - 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer - Google Patents
5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancerInfo
- Publication number
- CA3177056A1 CA3177056A1 CA3177056A CA3177056A CA3177056A1 CA 3177056 A1 CA3177056 A1 CA 3177056A1 CA 3177056 A CA3177056 A CA 3177056A CA 3177056 A CA3177056 A CA 3177056A CA 3177056 A1 CA3177056 A1 CA 3177056A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- pyrimidin
- triazolo
- phenyl
- pyridy1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994970P | 2020-03-26 | 2020-03-26 | |
| US62/994,970 | 2020-03-26 | ||
| PCT/EP2021/057807 WO2021191379A1 (en) | 2020-03-26 | 2021-03-25 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3177056A1 true CA3177056A1 (en) | 2021-09-30 |
Family
ID=75339741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3177056A Pending CA3177056A1 (en) | 2020-03-26 | 2021-03-25 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12528815B2 (https=) |
| EP (1) | EP4126873A1 (https=) |
| JP (1) | JP7774573B2 (https=) |
| KR (1) | KR20230051118A (https=) |
| CN (1) | CN115867280B (https=) |
| AU (1) | AU2021243725A1 (https=) |
| CA (1) | CA3177056A1 (https=) |
| WO (1) | WO2021191379A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| ATE457988T1 (de) | 2006-06-26 | 2010-03-15 | Schering Corp | A2a-adenosin-rezeptor-antagonisten |
| JP2011513417A (ja) * | 2008-03-04 | 2011-04-28 | シェーリング コーポレイション | アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物 |
| AU2011306358B2 (en) | 2010-09-24 | 2014-08-14 | Impetis Biosciences Ltd. | Fused tricyclic compounds as adenosine receptor antagonist |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| AU2018233367B2 (en) | 2017-03-16 | 2021-08-12 | Jiangsu Hengrui Medicine Co., Ltd. | Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof |
-
2021
- 2021-03-25 CA CA3177056A patent/CA3177056A1/en active Pending
- 2021-03-25 EP EP21715862.5A patent/EP4126873A1/en active Pending
- 2021-03-25 KR KR1020227037223A patent/KR20230051118A/ko active Pending
- 2021-03-25 CN CN202180038082.7A patent/CN115867280B/zh active Active
- 2021-03-25 US US17/914,196 patent/US12528815B2/en active Active
- 2021-03-25 JP JP2022558345A patent/JP7774573B2/ja active Active
- 2021-03-25 WO PCT/EP2021/057807 patent/WO2021191379A1/en not_active Ceased
- 2021-03-25 AU AU2021243725A patent/AU2021243725A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115867280B (zh) | 2025-05-27 |
| US12528815B2 (en) | 2026-01-20 |
| JP7774573B2 (ja) | 2025-11-21 |
| JP2023519361A (ja) | 2023-05-10 |
| EP4126873A1 (en) | 2023-02-08 |
| KR20230051118A (ko) | 2023-04-17 |
| CN115867280A (zh) | 2023-03-28 |
| AU2021243725A1 (en) | 2022-10-27 |
| WO2021191379A1 (en) | 2021-09-30 |
| US20230146483A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3647311B1 (en) | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof | |
| EP3601239B1 (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| KR101862493B1 (ko) | Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체 | |
| KR102476459B1 (ko) | 리신 특이적 데메틸라제-1의 억제제 | |
| EP3080100B1 (en) | Inhibitors of lysine specific demethylase-1 | |
| CA3217856A1 (en) | Heterocyclic compounds and methods of use | |
| TW202319056A (zh) | Ｓｈｐ２抑制劑及其用途 | |
| JP6581111B2 (ja) | Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体 | |
| KR20120124489A (ko) | 피페리딘 유도체 | |
| MX2012009613A (es) | Compuestos de pirrolo-pirimidina como inhibidores de dk4/6. | |
| MX2013009031A (es) | Derivados de piperidina puenteada. | |
| TW201127385A (en) | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | |
| CA3108676A1 (en) | Carboxamides as ubiquitin-specific protease inhibitors | |
| WO2007135529A2 (en) | Azabenzimidazolyl compounds as mglur2 potentiators | |
| EP4327877A2 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| JP2025532245A (ja) | Ａｋｔ１調節因子 | |
| AU2020300586A1 (en) | Heterocyclic compounds as kinase inhibitors | |
| CA3171012A1 (en) | Heteroaryl heterocyclic compounds and uses thereof | |
| EP2864331B1 (en) | Positive allosteric modulators of mglur2 | |
| CA3177056A1 (en) | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | |
| EP4373817A1 (en) | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer | |
| CA3113732A1 (en) | Aromatic heterocyclic compound with kinase inhibitory activity | |
| CA3259960A1 (en) | HETEROCYCLIC UREA AND AMIDE COMPOUNDS AS JAK2 INHIBITORS | |
| RU2229475C1 (ru) | 6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека | |
| WO2025194074A1 (en) | Kinase modulators and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240705 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250102 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250102 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250317 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250407 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250516 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260127 |